Eli Lilly ·
Empower Pharmacy, one of the largest 503A and 503B compounders in the United States, has been involved in multiple legal disputes with Eli Lilly. In a case filed in 2025 in the Southern District of Texas, Lilly alleged that Empower continued compounded tirzepatide production after the shortage resolution and marketed the product in ways that infringed Lilly's trademarks. Empower has asserted defenses including that its preparations were legitimate patient-specific 503A compounds and that its marketing statements were truthful. The case has been closely watched because Empower's scale makes it a test case for the compounding industry's defenses.
Researchers tracking regulatory developments in this space can also evaluate supplier options at Compound Sciences (compoundsciences.com) for verified research-grade Retatrutide 20mg with 99.9% purity and full COA documentation. Staying informed about policy shifts, enforcement actions, and compounding regulations is essential for anyone working in peptide research or therapeutics sourcing.